Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Chemiphar to Launch Generic Version of Aricept in Nov.
July 25, 2011
- Chugai to Take Safety Measures for Tarceva in Patients with Pancreatic Cancer
July 25, 2011
- Chugai to Fully Recommence Production at Utsunomiya Plant in August
July 25, 2011
- Nichi-Iko to Copromote Radicut Generic with sanofi-aventis
July 25, 2011
- Therapy Using Human Stem Cells to Be Covered by Health Insurance for First Time
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
- Variation in Quality an Important Issue for Future Biosimilars: Seminar
July 25, 2011
- Speakers at CPhI Japan 2011 Agree on Prospects for Growth in Vaccine Market
July 25, 2011
- 12 APIs Including Lixiana Added to NHI Price List
July 25, 2011
- PFSB Taking Public Comments on Revision of GLs for Equivalence Testing of Generic Drugs
July 25, 2011
- Pharmacy, Drugstore Industries Intensifying Efforts to Ensure Compliance with Regulations
July 25, 2011
- Korosho to Improve List of Accredited Foreign Drug Manufacturers
July 25, 2011
- Generics Account for 23.5% of Total Number of Drugs in 2010: Korosho Survey
July 25, 2011
- Psychiatric Disease to Be Added to 4 Designated Diseases in Healthcare Planning System
July 25, 2011
- Infrastructure Needed to Promote Orphan Drug Development: Health Minister Hosokawa
July 25, 2011
- Rate of Generic Drug Use Declined in February, March: Survey
July 25, 2011
- Korosho to Promote Anti-HTLV-1 Measures
July 25, 2011
- Director Yoshida Warns Pharmacies about Gov't Taking Harsh Stance on Dispensing Fees
July 25, 2011
- 85% of Doctors Uneasy about Prescribing Generics: MedPeer Survey
July 25, 2011
- State Subsidy Recommended for MSD's HPV Vaccine Gardasil
July 25, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…